磷酸单十八烷醇酯 | 2958-09-0

• 物质功能分类: 有机原料 - 无机酸酯
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磷酸及其衍生物
• 中文名称: 磷酸单十八烷醇酯
• 中文别名: 硬脂醇磷酸酯
• 英文名称: monostearyl phosphate
• 英文别名: phosphoric acid stearyl monoester；octadecylphosphate；octadecyl phophosphate；phosphoric acid mono-n-octadecyl ester；Phosphorsaeure-monooctadecylester；phosphoric Acid Monooctadecyl Ester；Octadecyl-dihydrogenphosphat；Monostearylphosphorsaeure；Monooctadecylphosphat；n-Octadecylphosphat；stearylphosphoric acid ester；mono-n-octadecyl phosphate；monooctadecyl phosphate；stearyl phosphate；NSC 41920；octadecyl dihydrogen phosphate
• CAS: 2958-09-0
• 化学式: C₁₈H₃₉O₄P
• 分子量: 350.479
• InChiKey: UHGIMQLJWRAPLT-UHFFFAOYSA-N

物化性质

• 沸点：
  465.6±28.0 °C(Predicted)
• 密度：
  0.997±0.06 g/cm3(Predicted)
• 物理描述：
  Stearyl acid phosphate appears as a white waxy solid. Insoluble in water. Vapor or liquid may irritate of severely burn skin or eyes. Inhalation may irritate and seriously burn respiratory tract. Ingestion may irritate and burn mucous membranes of the gastrointestinal tract.

计算性质

• 辛醇/水分配系数(LogP)：
  7.3
• 重原子数：
  23
• 可旋转键数：
  18
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2919900090

反应信息

• 作为反应物：
  描述：

  磷酸单十八烷醇酯 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 41.0h， 生成 2'-2'-difluoro-deoxycytidine-5'-octadecylphosphate
  参考文献：
  名称：

  LIPOPHILIC MONOPHOSPHORYLATED DERIVATIVES AND NANOPARTICLES

  摘要：

  其中提供了伊立替宾的亲脂性单磷酸化衍生物，还提供了包含伊立替宾的亲脂性单磷酸化衍生物的纳米粒子组合物、相应的药物组合物，以及一种治疗癌症或病毒感染的方法，该方法包括给需要的受试者使用本文披露的药物组合物。

  公开号：

  US20130131008A1
• 作为产物：
  描述：

  硬脂醇 在 N-丁基咪唑 、 三正丁胺 、 磷酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 磷酸单十八烷醇酯
  参考文献：
  名称：

  通过亲核碱促进的磷酸和醇的脱水缩合选择性合成磷酸单酯。

  摘要：

  磷酸单酯是在三丁胺存在下由磷酸（1或2当量）和醇（1当量）的混合物合成的。该反应由亲核碱如N-烷基咪唑和4-（N，N-二烷基氨基）吡啶促进。2'，3'-O-异亚丙基核糖核苷被选择性地转化为5'-单磷酸酯，而没有保护核碱基中的氨基。

  DOI：

  10.1021/ol0504796

文献信息

• [EN] TRIAZINE DERIVATIVES AS UV ABSORBERS<br/>[FR] DERIVES DE LA TRIAZINE UTILISES COMME ABSORBANTS U.V.
  申请人：CIBA SC HOLDING AG

  公开号：WO2004064797A1

  公开（公告）日：2004-08-05

  The present invention relates to new compounds of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, and R8 independently from each other are hydrogen; C1-C18alkyl; C2-C18alkenyl; C5-C7,cycloalkyl; C1-C6alkylene-C5- C7,cycloalkyl; R9 is hydrogen; C1-C18alkyl; C2-C18alkenyl; C5-C7cycloalkyl; C1-C6alkylene-C5-C7cycloalkyl; C6-C10aryl; A is-S-; -O- or -NR10-, wherein R10 has the same meanings as R9; X is COOR11; CONR12R13; SO3,R14; or SO2NR15R16, wherein R11, R12,R13, R14,R15, and R16, have independently from each other the same meanings as R9; to their preparation and to their use as UV absorbers in cosmetic and pharmaceutical formulations.

  本发明涉及公式（I）的新化合物，其中R1、R2、R3、R4、R5、R6、R7和R8彼此独立地是氢；C1-C18烷基；C2-C18烯基；C5-C7环烷基；C1-C6烷基-C5-C7环烷基；R9是氢；C1-C18烷基；C2-C18烯基；C5-C7环烷基；C1-C6烷基-C5-C7环烷基；C6-C10芳基；A是-S-；-O-或-NR10-，其中R10具有与R9相同的含义；X是COOR11；CONR12R13；SO3R14；或SO2NR15R16，其中R11、R12、R13、R14、R15和R16彼此独立地具有与R9相同的含义；以及它们的制备和它们作为化妆品和药用配方中的紫外线吸收剂的用途。
• RECORDING MATERIAL PRODUCED USING NON-PHENOL COMPOUND
  申请人：NIPPON SODA CO., LTD.

  公开号：US20150284321A1

  公开（公告）日：2015-10-08

  An object of the present invention is to provide a recording material or a recording sheet using, as a color-developing agent, a non-phenol compound that is a safe compound in no danger of corresponding to an endocrine disruptor and is good in color developing performance. The non-phenol compound used in the present invention is at least one selected from the group consisting of compounds represented by the following formulas (I) to (III).

  本发明的目的是提供一种使用非酚类化合物作为显色剂的记录材料或记录纸，该非酚类化合物是一种安全化合物，不会对应到内分泌干扰物，并且在显色性能方面表现良好。本发明中使用的非酚类化合物至少选自以下化合物所代表的化合物组，其化学式为(I)至(III)。
• LPA receptor agonists and antagonists and methods of use
  申请人：——

  公开号：US20030130237A1

  公开（公告）日：2003-07-10

  The present invention relates to compounds according to formula (I) as disclosed herein as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, treating a wound, treating apoptosis or preserving or restoring function in a cell, tissue, or organ, culturing cells, preserving organ or tissue function, and treating a dermatological condition.

  本发明涉及根据所述的化合物的化学式(I)，以及包括这些化合物的药物组合物。还公开了使用这些化合物的方法，这些方法具有作为LPA受体的激动剂或拮抗剂的活性；这些方法包括抑制LPA对LPA受体的活性，调节LPA受体的活性，治疗癌症，增强细胞增殖，治疗伤口，治疗凋亡或保护或恢复细胞、组织或器官的功能，培养细胞，保护器官或组织功能，以及治疗皮肤病症。
• 6-Alkyl-, 6-aryl- or 6-hetaryl-7-deazapurine ribonucleosides as inhibitors of human or MTB adenosine kinase and potential antimycobacterial agents
  作者：Pavla Perlíková、Petr Konečný、Petr Nauš、Jan Snášel、Ivan Votruba、Petr Džubák、Iva Pichová、Marián Hajdúch、Michal Hocek

  DOI：10.1039/c3md00232b

  日期：——

  Title 6-alkyl-, 6-aryl- and 6-hetaryl-7-deazapurine ribonucleosides previously known as nanomolar cytostatics were found to be potent inhibitors of either human or mycobacterial (MTB) adenosine kinase (ADK). Several new derivatives bearing bulky substituents at position 6 were non-cytotoxic but selectively inhibited MTB ADK. However, most of the nucleosides (ADK inhibitors) as well as their octadecylphosphate prodrugs were inactive in the whole cell assay of inhibition of Mycobacterium bovis growth. 6-Methyl-7-deazapurine ribonucleoside was found to be a potent antimycobacterial agent.

  标题：6-烷基、6-芳基和6-杂芳基-7-脱氮嘌呤核糖核苷，先前被称为纳摩尔级的细胞抑制剂，被发现是强效的人类或分枝杆菌（MTB）腺苷激酶（ADK）抑制剂。一些在6位带有大体积取代基的新衍生物无细胞毒性，但能选择性地抑制MTB ADK。然而，大多数核苷（ADK抑制剂）及其十八烷基磷酸前药在抑制牛分枝杆菌生长的整体细胞试验中均无活性。6-甲基-7-脱氮嘌呤核糖核苷被发现是一种强效的抗分枝杆菌剂。
• Fatty Alcohol Phosphates are Subtype-Selective Agonists and Antagonists of Lysophosphatidic Acid Receptors
  作者：Tamas Virag、Don B. Elrod、Karoly Liliom、Vineet M. Sardar、Abby L. Parrill、Kazuaki Yokoyama、Gangadhar Durgam、Wenlin Deng、Duane D. Miller、Gabor Tigyi

  DOI：10.1124/mol.63.5.1032

  日期：2003.5.1

  A more complete understanding of the physiological and pathological role of lysophosphatidic acid (LPA) requires receptor subtype-specific agonists and antagonists. Here, we report the synthesis and pharmacological characterization of fatty alcohol phosphates (FAP) containing saturated hydrocarbon chains from 4 to 22 carbons in length. Selection of FAP as the lead structure was based on computational modeling as a minimal structure that satisfies the two-point pharmacophore developed earlier for the interaction of LPA with its receptors. Decyl and dodecyl FAPs (FAP-10 and FAP-12) were specific agonists of LPA2 (EC50 = 3.7 ± 0.2 μM and 700 ± 22 nM, respectively), yet selective antagonists of LPA3 ( K i = 90 nM for FAP-12) and FAP-12 was a weak antagonist of LPA1. Neither LPA1 nor LPA3 receptors were activated by FAPs; in contrast, LPA2 was activated by FAPs with carbon chains between 10 and 14. Computational modeling was used to evaluate the interaction between individual FAPs (8 to 18) with LPA2 by docking each compound in the LPA binding site. FAP-12 displayed the lowest docked energy, consistent with its lower observed EC50. The inhibitory effect of FAP showed a strong hydrocarbon chain length dependence with C12 being optimum in the Xenopus laevis oocytes and in LPA3-expressing RH7777 cells. FAP-12 did not activate or interfere with several other G-protein-coupled receptors, including S1P-induced responses through S1P1,2,3,5 receptors. These data suggest that FAPs are ligands of LPA receptors and that FAP-10 and FAP-12 are the first receptor subtype-specific agonists for LPA2.

  对溶血磷脂酸（LPA）的生理和病理作用进行更全面的理解，需要针对不同受体亚型的激动剂和拮抗剂。本文报道了含有4至22个碳的饱和碳氢链的脂肪醇磷酸盐（FAP）的合成和药理学特性。选择FAP作为主要结构是基于计算模型，该模型以满足先前为LPA与其受体相互作用而开发的两点药效团的最小结构为基础。癸基和十二烷基FAP（FAP-10和FAP-12）分别是LPA2的特异性激动剂（EC50分别为3.7±0.2μM和700±22nM），同时也是LPA3的选择性拮抗剂（FAP-12的K i为90nM），而FAP-12对LPA1是弱的拮抗剂。FAP既不能激活LPA1也不能激活LPA3受体；相反，LPA2被含10至14个碳链的FAP激活。通过计算模拟，将每个化合物对接在LPA结合位点，来评估单个FAP（8至18）与LPA2的相互作用。FAP-12显示最低的对接能，与其较低的观察EC50一致。FAP的抑制效应显示出强烈的碳氢链长度依赖性，在非洲爪蟾卵母细胞和表达LPA3的RH7777细胞中，C12是最适长度。FAP-12未激活或干扰包括S1P1,2,3,5受体介导的S1P反应在内的几个其他G蛋白偶联受体。这些数据表明FAP是LPA受体的配体，且FAP-10和FAP-12是首批针对LPA2受体亚型的特异性激动剂。

表征谱图